Acute hepatitis C
alanine aminotransferase levels 102–104
clinical features 102–106
fulminant hepatitis 106
hepatocellular carcinoma, natural course 168, 169
histology of liver 119
incubation period
chimpanzees 259
humans 102, 103
interferon-α therapy 189, 191
recurrent infection chimpanzees 253–255
humans 104, 105
T helper cell response 141–143
Autoimmune hepatitis (AIH), see Autoimmune hepatitis
Alanine aminotransferase (ALT)
levels in acute hepatitis C 102–104
alanine aminotransferase screening 240, 242
antibody screening 239–242, 246–248
Alcohol, effects
chronic hepatitis C outcome 111
hepatocellular carcinoma 167
ALT, see Alanine aminotransferase
Antibody autoantibody, see Autoantibody
diagnosis, screening and confirmation of antibodies
blood donor screening 211
evaluation of systems 242–246
first generation assays 64–66
Japan experience, impact on posttransfusion hepatitis 239–242, 246–248
limitations 76
second generation assays 66–69
third generation assays 69–73
epidemiological analysis 211–213
humoral response to hepatitis C virus 136, 137
neutralization of virus 66, 137, 255–257
Antisense oligonucleotide, antiviral strategy 24, 25
Autoantibody
chronic hepatitis C association 108, 156, 157
induction by interferon-α 192
liver-kidney microsomal autoantibodies
autoimmune hepatitis association 155, 156
hepatitis C association 155, 156
types 155
Autoimmune hepatitis (AIH)
differential diagnosis 157, 158
hepatitis C virus antibody prevalence 152–155, 157
Blood transfusion
donor screening
alanine aminotransferase levels 210, 211, 225, 226
antibody testing 224–226
hepatitis C risk 213–215
Japan experience
evaluation of serologic screening systems 242–246
impact on disease
alanine aminotransferase screening 240, 242
antibody screening 239–242, 246–248
number of transfused units 239
posttransfusion hepatitis trends 237, 238
Branched-DNA assay, viral RNA detection in blood 76, 79, 81, 87
C
multimerization 13
phosphorylation 12, 13
processing 12
protein–protein interactions 13, 14
proteolytic processing by host 6, 7
subcellular localization 12, 13
transcriptional regulation 13
Capsid/core protein, see C
Carcinoma, see Hepatocellular carcinoma
CD4+ T cell, see T helper cell
CD8+ T cell, see Cytotoxic T lymphocyte
Chronic hepatitis C
autoantibodies 108
chimpanzee patterns of infection 258, 259
clinical features 107–109, 181
interferon-α therapy in children 191
liver biopsy
classification and scoring systems 123–128
C (continued)
clinical feature correlation 130
histology 119–121
histopathological correlations 128–130
indications 122, 123
therapy response correlation 131, 132
virological feature correlation 130, 131
long-term outcome
alcohol effects 111
cirrhosis 109–113
hepatitis B virus effects 110
hepatocellular carcinoma association 113, 161
natural course 169, 170
immune system factors 110, 111
mortality 112
ribavirin therapy
elicacy 196
interferon-α combination therapy 196, 197
T helper cell response 143–145, 148
Cirrhosis
chronic hepatitis C association 109–113
hepatocellular carcinoma, natural course 170, 171
histology of liver 121, 122
Complementary DNA-polymerase chain reaction, see Polymerase chain reaction
Cytotoxic T lymphocyte
antigen presentation 139
antiviral response 138
response in hepatitis C chimpanzees 257
cytokines 146
measurement 140, 141, 147
vaccine development 145, 146
Diagnosis
antibody screening and confirmation
effect on historical epidemiological data 211, 212
first generation assays 64–66
limitations 76
second generation assays 66–69
third generation assays 69–73
autoimmune hepatitis, differential diagnosis 157, 158
RNA detection in blood
amplification
branched-DNA assay 76, 79, 81, 87
complementary DNA-polymerase chain reaction 76, 77, 83, 84, 86, 87
nucleic acid sequence-based amplification 76–78, 83, 86, 87
quantitative analysis 85, 86
validation and standardization 86, 87
copy abundance in plasma 76
detection of amplified products 84, 85
diagnostic applications 88
RNA extraction 82, 83
sample collection, preparation and storage 81, 82
serologic assay validation and blood testing 89
transmission analysis 91, 92
RNA detection in tissue 93
E1
E2 interactions 14, 15
subcellular localization 14
vaccination target 15, 16, 54
variable region 15, 44, 46, 50
E2
E1 interactions 14, 15
hypervariable regions 15, 44, 50, 136
subcellular localization 14
vaccination target 15, 16, 54
ELISA, see Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA), serological diagnosis by
antibody screening
first generation assays 65
genotype effects on sensitivity 53
neutralization assay 66
second generation assays 67
sensitivity effect on historical epidemiological data 211, 212
third generation assays 69, 70
Epidemiology, see Transmission
Flaviviridae, classification 38–41
Fulminant hepatitis, acute hepatitis C association 106
Genome
cloning 1, 2
genotypes, see Genotype
mutation rate 15, 43, 44, 46
organization 3, 64
replication
cell lines for study 22, 23
intrahepatic localization in chimpanzee 259, 260, 262
mechanism 22
polymerase chain reaction assays of natural history 90, 91
retrovirus facilitation 23, 90
3′ untranslated region elements 21
sequencing 20, 21
5′ untranslated region
homology with other viruses 3
internal ribosome entry site activity 5
secondary structure 4, 5
Genotype
assays 49, 93
classification 41, 42
disease progression effects 54, 55
divergence 48, 49
diversification 46
effects on α-interferon response 55, 56
epidemiology applications 52, 53
geographical distribution 43
hepatocellular carcinoma, effects on development 172–174
origins 46–48
HAI, see Histological activity index
HCC, see Hepatocellular carcinoma
Hemodialysis, hepatitis C risk 216, 217
Hemophilia, hepatitis C risk from blood products 215, 216
Hepatitis A, transmission 1, 210, 211
Hepatitis B, hepatocellular carcinoma
clinical features of development 165, 166
synergism with hepatitis C 166
immune response 135, 252
transmission 1, 210, 211
Hepatitis C virus, see also Acute hepatitis C, Chronic hepatitis C
classification 38–41
diagnosis, see Diagnosis
genome, see Genome
genotyping, see Genotype
persistence, see Persistence
quasispecies 49–51
transmission, see Transmission
vaccination, see Vaccination
Hepatitis D, transmission 210, 211
Hepatitis G, hepatocellular carcinoma 167
Hepatocellular carcinoma (HCC)
chimpanzee model 257, 258
chronic hepatitis C association 113, 161
clinical features of hepatitis B and C disease 165, 166
epidemiology
geographical distribution 161, 162
overview 161
prevalence from hepatitis 163
trends in Japan 163–165
genotype effects on development 172–174
natural course in hepatitis C infection
acute hepatitis C 168, 169
carriers 167, 168
chronic hepatitis C 169, 170
cirrhosis 170, 171
comparison with hepatitis B infection 171, 172
oncogenicity of hepatitis C 174, 175
synergistic factors in hepatitis C-related disease
alcohol 167
hepatitis B virus infection 166
hepatitis G virus infection 167
Histological activity index (HAI), scoring of liver biopsies 124, 128
Histology, see Liver biopsy
Hak scoring system, scoring of liver biopsies 125, 127, 128
Interferon-α
evaluation of response 91, 184, 185, 189
genes 183
genotype effects on response 55, 56
hepatitis C virus treatment efficacy 24, 183–185, 199
acute hepatitis C 189, 191
chronic hepatitis C treatment in children 191
history of use 182
mechanism of action 183
predictors of response 185, 188
receptors 183
relapse and retreatment 188
ribavirin combination therapy 196, 197, 199, 200
side effects autoimmune induction 192
bone marrow suppression 192
liver failure 193
psychiatric effects 192
retinopathy 193
treatment with normal alanine aminotransferase levels 188, 189
Internal ribosome entry site (IRES)
anisense oligonucleotide targeting 24, 25
polypyrimidine-tract-binding protein function 5, 6
5′ untranslated region activity 5
Intravenous drug use, transmission of hepatitis C
quasispecies 49–51
transmission, see Transmission 213, 216, 221–223
Liver biopsy
classification and scoring systems 123–128
clinical feature correlation 130
histology
acute hepatitis C 119
chronic hepatitis C 119–121
cirrhosis 121, 122
histopathological correlations 128–130
indications 122, 123
replication localization in chimpanzee 259, 260, 262
therapy response correlation 131, 132, 189
virological feature correlation 130, 131
Liver-kidney microsomal (LKM)
autoantibodies
autoimmune hepatitis association 155, 156
hepatitis C association 155, 156
types 155
Liver transplantation
outcomes in hepatitis C 198
recurrence of virus infection 197–199
LKM autoantibodies, see Liver-kidney microsomal autoantibodies
Nonstructural protein 2, see NS2
Nonstructural protein 3, see NS3
Nonstructural protein 4A, see NS4A
Nonstructural protein 5A, see NS5A
Nonstructural protein 5B, see NS5B
polyprotein processing 16
proteolytic processing by host 6
NS2-3 protease
catalytic mechanism 11
discovery 10
purification 11, 12
Subject Index

270

NS3
assays 9, 10
catalytic mechanism 7
effects on protein kinase A activity 17
epitopes 142, 143
helicase activity 16, 17
inhibitors 10
NTPase activity 16, 17
proteolytic processing of viral proteins 7, 8
structure 8, 9
zinc binding 9
NS4A
polyprotein processing role 17, 18
T helper cell response 143–145
NS5A
interferon-sensitivity-determining region 18, 19
phosphorylation 18
NS5B
RNA polymerase activity 19, 20
subcellular localization 20
variability 44
p7, properties 16
PCR, see Polymerase chain reaction
Persistence
mechanisms 49–52, 148
prevalence 106, 107
Polymerase chain reaction (PCR) RNA detection in blood
amplification
complementary DNA-polymerase chain reaction 76, 77, 83, 84, 86, 87
nucleic acid sequence-based amplification 76–78, 83, 86, 87
quantitative analysis 85, 86
validation and standardization 86, 87
antiviral therapy analysis 91
copy abundance in plasma 76
detection of amplified products 84, 85
diagnostic applications 88
genotyping 93
natural history analysis 90, 91
RNA extraction 82, 83
sample collection, preparation and storage 81, 82
serologic assay validation and blood testing 89
transmission analysis 91, 92
RNA detection in liver and cells 93
Polymerase inhibitor, antiviral strategy 23
Polypyrimidine-tract-binding protein (PTB), internal ribosome entry site function 5, 6
Protease inhibitor, antiviral strategy 23, 24, 197
Protein kinase A, inhibition by NS3 17
PTB, see Polypyrimidine-tract-binding protein
Recombinant immunoblot assay (RIBA), confirmation of HCV antibodies
first generation assays 65, 66
second generation assays 67
third generation assays 70
Replication, see Genome
RIBA, see Recombinant immunoblot assay
Ribavirin
chronic hepatitis C treatment efficacy 196
interferon-α combination therapy 196, 197, 199, 200
mechanism of action 193, 196
side effects 197
Scheuer scoring system, scoring of liver biopsies 125, 126, 128
T cell, see Cytotoxic T lymphocyte, T helper cell
T helper cell
antigen presentation 139
cytokine secretion and regulation 137, 138
response
acute hepatitis C 141–143
cytokine secretion and regulation 137, 138
chronic hepatitis C 143–145, 148
measurement 139, 140
viral clearance 145
types 137
Transfusion, see Blood transfusion
Transmission
analysis by viral RNA detection 91, 92
chimpanzee
fecal-oral transmission 252
vertical transmission 252
health care workers 217, 218
hemodialysis patients 216, 217
hemophilia patients 215, 216
history of epidemiology
antibody testing sensitivity and prevalence of disease 211–213
parenteral non-A, non-B hepatitis 208, 209
sporadic non-A, non-B hepatitis 209, 210
prevention
blood donor screening 224–227
inactivation of plasma derivatives 227, 251
vaccination 227
risk factors
blood transfusion 213–215
intravenous drug use 213, 216, 221–223
sexual promiscuity 213, 214
sexual transmission 221–223
vertical transmission and intrafamilial spread 218–221
Untranslated regions, see Genome
Vaccination
chimpanzee models 261
E1 and E2 as targets 15, 16, 54
Virion
density 2
particle size 2, 3
Western blot, confirmation of HCV antibodies 70, 71